A haplotype at the DBH locus, associated with low plasma dopamine β-hydroxylase activity, also associates with cocaine-induced paranoia

Molecular Psychiatry

Volumn 5, Issue 1, 2000, Pages 56-63

  Cubells, J F ^a,b   Kranzler, H R ^c   McCance Katz, E ^a,b,d   Anderson, G M ^e   Malison, R T ^a,f   Price, L H ^a,f,g   Gelernter, J ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Yale University School of Medicine   (United States)

^g BUTLER HOSPITAL   (United States)

Author keywords

Alleles; Catecholamines; Central nervous system stimulants; Genes; Norepinephrine; Psychotic disorders; Schizophrenia; Substance related disorders

Indexed keywords

COCAINE; DOPAMINE BETA MONOOXYGENASE;

ALLELE; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EUROPE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; QUANTITATIVE TRAIT; UNITED STATES;

EID: 0033966753     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000657     Document Type: Article

References (47)

1. 1 Satel SL, Southwick S, Gawin F. Clinical features of cocaine-induced paranoia. Am J Psychiatry 1991; 148: 495-499.
2. 2 Brady KT, Lydiard RB, Malcolm R, Ballenger JC. Cocaine-induced psychosis. J Clin Psychiatry 1991; 52: 509-511.
3. 3 Rosse RR, Fay-McCarthy M, Collins Jr JP, Alim TN, Deutsch SI. The relationship between cocaine-induced paranoia and compulsive foraging: a preliminary report. Addiction 1994; 89: 1097-1104.
4. 4 Satel SL, Edell WS. Cocaine-induced paranoia and psychosisproneness. Am J Psychiatry 1991; 148: 1708-1711.
5. 5 Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 1997; 132: 107-124.
6. 6 Boutros N, Krystal J, Gelernter J. Sensory gating and cocaine induced paranoia. Biol Psychiatry 1998; 43: 89S.
7. 7 Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997; 94: 587-592.
8. 8 Brady K, Anton R, Ballenger JC, Lydiard B, Adinoff B, Selander J. Cocaine abuse among schizophrenic patients. Am J Psychiatry 1990; 147: 1164-1167.
9. 9 Lysaker P, Bell M, Beam-Goulet J, Milstein R. Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J Nerv Mental Dis 1994; 182: 09-112.
10. 10 Gelernter J, Kranzler HR, Satel SL, Rao PA. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 1994; 11: 195-200.
11. 11 Nurnberger JI, Gershon ES, Simmons S, Ebert M, Kessler LR, Dibble ED et al. Behavioral, biochemical, and neuroendocrine responses to amphetamine in normal twins and 'well-state' bipolar patients. Psychoneuroendocrinology 1982; 7: 163-176.
12. 12 Lyons MJ, Toomey R, Meyer JM, Green AI, Eisen SA, Goldberg J et al. How do genes influence marijuana use? The role of subjective effects. Addiction 1997; 92: 409-417.
13. 13 Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. Oxford University Press: New York, 1986.
14. 14 Dunnette J, Weinshilboum RM. Human serum dopamine-β-hydroxylase: correlation of enzyme activity with immunoreactive protein in genetically defined samples. Am J Hum Genet 1976; 28: 155-166.
15. 15 O'Connor DT, Levine GL, Frigon RP. Homologous radio-immunoassay of human plasma dopamine β-hydroxylase: analysis of homospecific activity, circulating plasma pool and intergroup differences based upon race, blood pressure and cardiac function. J Hypertension 1983; 1: 227-233.
16. 16 O'Connor DT, Cervenka JH, Stone RA, Levine GL, Parmer RJ, Franco-Bourland RE et al. Dopamine β-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson's disease and congenital dopamine β-hydroxylase deficiency, Clin Sci 1994; 86: 148-158.
17. 17 Weinshilboum RM. Serum dopamine-β-hydroxylase. Pharmacol Rev 1978; 30: 133-166.
18. 18 Oxenstierna G, Edman G, Iselius L, Oreland L, Ross SB, Sedvall G. Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals - a genetic study. J Psychiat Res 1986; 20: 19-29.
19. 19 Goldin LR, Gershon ES, Lake CR, Murphy DL, McGinniss M, Sparkes RS. Segregation and linkage studies of plasma dopaminebeta-hydroxylase (DBH), erythrocyte catechol-O-methyl transferase (COMT) and platelet monoamine oxidase (MAO): possible linkage between tbe ABO locus and a gene controlling DBH activity. Am J Hum Genet 1982; 34: 250-262.
20. 20 Wilson AF, Elston RC, Siervogel RM, Tran LD. Linkage of a gene regulating dopamine-β-hydroxylase activity and the ABO blood group locus. Am J Hum Genet 1988; 42: 160-166.
21. 21 Wei J, Ramchand CN, Hemmings GP. Possible control of dopamine β-hydroxylase via a codominant mechanism associated with the polymorphic (GT), repeat at its gene locus in healthy individuals. Hum Genet 1997; 99: 52-55.
22. 22 Cubells JF. Van Kammen DP, Kelley ME, Anderson GM, O'Connor DT, Price LH et al. Dopamine β-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet 1998; 102: 533-540.
23. 23 Sternberg DF, Van Kammen DP, Lerner P, Bunney WE. Schizophrenia: dopamine-β-hydroxylase activity and treatment response. Science 1982; 216: 1423-1425.
24. 24 Van Kammen DP, Kelley ME, Gilbertson MW, Gurklis J, O'Connor DT. CSF dopamine β-hydroxylase in schizophrenia: associations with premorbid functioning and brain computerized tomography scan measures. Am J Psychiatry 1994; 151: 372-378.
25. 25 Meltzer HY, Hyong HW, Carroll BJ, Russo P. Serum dopamine-β-hydroxylase in the affective psychoses and schizophrenia: decreased activity in unipolar psychotically depressed patients. Arch Gen Psychiatry 1976; 33: 585-591.
26. 26 Mód L, Rihmer Z, Magyar I, Arató M, Alföldi A, Bagdy G. Serum DBH activity in psychotic vs nonpsychotic unipolar and bipolar depression. Psychiatry Res 1986; 19: 331-333.
27. 27 Sapru MK, Rao BSSR, Channabasavanna SM. Serum dopamine-β-hydroxylase activity in clinical subtypes of depression. Acta Psychiatr Scand 1989; 80: 474-478.
28. 28 Meyers BS, Alexopoulos GS, Kakuma T, Tirumalesetti F, Gabriele M, Alpert S et al. Decreased dopamino beta-hydroxylase activity in unipolar geriatric delusional depression. Biol Psychiatry 1999; 45: 448-442.
29. 29 Kobayashi K, Kiuchi K, Ishii A, Kaneda N, Kurosawa Y, Fujita K et al. Human dopamine β-hydoxylasc gene: two mRNA types having different 3-terminal regions are produced through alternative polyadenylation. Nucl Acids Res 1989; 17: 1089-1102.
30. 30 Cubells JF, Kobayashi K, Nagatsu T, Kidd KK, Kidd JR. Galafell F et al. Population genetics of a functional variant of the dopamine β-hydroxylase gene (DBH). Am J Med Genet (Neuropsychiatrie Genet) 1997; 74: 374-379.
31. 31 Gelernter J, Kranzler H, Satel SL. No association between D2 dopamine receptor alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European-or African Americans. Biol Psychiatry 1999; 45: 340-345.
32. 32 Nahmias J, Burley MW, Povey S, Porter C, Craig I, Wolfe J. A 19 bp deletion polymorphism adjacent to a dinucleotide repeat polymorphism at the human dopamine beta-hydroxylase locus. Hum Molec Gen 1992; 1: 286.
33. 33 Long JC, Williams RC, Urbanek M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 1995; 56: 799-810.
34. 34 Lewontin RC. On measures of gametic disequilibrium. Genetics 1988; 120: 849-852.
35. 35 Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59: 97-105.
36. 36 Craig SP, Buckle VJ, Lamaroux A, Malet J, Craig IW. Localization of the human dopamine beta-hydroxylase (DBH) gene to chromosome 9q34. Cytogenet Cell Genet 1988; 48: 48-50.
37. 37 Gelernter J, Gejman PV, Bisighini S, Kidd KK. Sequence lagged site (STS) TaqI RFLP at dopamine β-hydroxylase (DBH). Nucl Acids Res 1991; 19: 1957.
38. 38 Perry SE, Summar L, Phillips JA, Robertson D. Linkage analysis of the human dopamine β-hydroxylase gene. Genomics 1991; 10: 493-495.
39. 2 dopamine receptor gene and alcoholism: a reappraisal. JAMA 1993; 269: 1673-1677.
40. 40 Gejman PV, Gelernter J. Mutational analysis of candidate genes in psychiatric disorders. Am J Med. Genet (Neuropsychiatric Genet) 1993; 48: 184-191.
41. 41 Kidd KK, Pakstis AJ, Castiglione CM, Kidd JR, Speed WC, Goldman D et al. DRD2 haplotypes containing the taq I A1 allele: implications for alcoholism research. Alcoholism: Clin Exp Res 1996; 20: 697-705.
42. 42 Carroll KM, Nich C, Ball SA, McCance E, Rounsaville BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998; 93: 713-728.
43. 43 Petrakis IL, Carrol KM, Nich C, Gordon L, McCance-Katz EL, Frankforter T et al. Disulfiram treatment for cocaine dependence in methadone maintained opioid addicts. Addiction (in press).
44. 44 Hameedi FA, Rosen MI, McCance-Katz EF, MCMahon T), Price LH, Jatlow PI et al. Behavioral, physiological and pharmacological interaction of cocaine and disulfiram. Biol Psychiatry 1995; 37: 560-563.
45. 45 McCance-Katz EF, Kosten TR, Jatlow P. Chronic disulfiram treatment effects on intranasal cocaine administration: initial results. Biol Psychiatry 1998; 43: 540-543.
46. 46 McCance-Katz EF, Kosten TR, Jatlow P. Disulfiram effects on acute cocaine administration. Drug Alc Dep 1998; 52: 27-39.
47. 47 Major LF, Lerner P, Ballenger JC, Brown GL, Goodwin FK, Lovenberg W. Dopamine β-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry 1979; 14: 337-344.